Project Name Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility
Project Number 54171-003
Country / Economy Philippines
Project Status Closed
Project Type / Modality of Assistance Loan
Source of Funding / Amount
Loan 4050-PHI: Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility
Ordinary capital resources US$ 400.00 million
Loan 8394-PHI: Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility
Asian Infrastructure Investment Bank US$ 300.00 million
Loan 4163-PHI: Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility - Additional Financing
Ordinary capital resources US$ 250.00 million
Operational Priorities OP1: Addressing remaining poverty and reducing inequalities
OP2: Accelerating progress in gender equality
OP7: Fostering regional cooperation and integration
Sector / Subsector

Health / Disease control of communicable disease

Gender Effective gender mainstreaming
Description

The proposed loan to the Republic of the Philippines for the Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility (HEAL 2). Under the rapid response component (RRC) of the Asia Pacific Vaccine Access Facility (APVAX), will provide the Government of the Philippines with timely financing for safe and effective vaccine procurement and logistics, based on an agreed list of eligible expenditures. It will supplement the initial support of the Asian Development Bank (ADB) to the government's coronavirus disease (COVID-19) response under the Health System Enhancement to Address and Limit COVID-19 (HEAL) project. HEAL 2 is aligned with three operational priorities of ADB's Strategy 2030: (i) addressing remaining poverty and reducing inequalities; (ii) accelerating progress in gender equality; and (iii) fostering regional cooperation and integration.

The Philippines has met all APVAX access criteria by (i) demonstrating the adverse impact of the COVID-19 pandemic; (ii) completing a needs assessment and a vaccination allocation and prioritization plan, including an incremental medical waste management plan and procurement arrangements acceptable to ADB, with ADB's receipt of a Governor's letter confirming its commitment to implement the plan and ensure compliance with the APVAX vaccine eligibility criteria; and (iii) establishing an effective development partner coordination mechanism with a clear role for ADB

Project Rationale and Linkage to Country/Regional Strategy

Status of the pandemic in the Philippines. The Philippines recorded its first case of COVID-19 on 30 January 2020, and the first case of local transmission on 7 March 2020. Given the threat of COVID-19 to national security, a State of Public Health Emergency was declared on 8 March 2020 through Proclamation No. 922, and the National Capital Region was placed under general community quarantine on 15 March 2020. This was escalated to an enhanced community quarantine for the whole of Luzon on 16 March 2020 to mitigate the spread of the virus. On 16 May 2020, the government started to relax the quarantines and the associated nonpharmaceutical interventions (NPIs) because of the observed stabilization of the number of new cases. However, new cases started to rapidly emerge again by July 2020.

The rapid surge prompted a re-imposition of stricter quarantine measures and NPIs by August 2020. As a result, the weekly increases in new COVID-19 cases were reduced from a peak of 23,019 during 6-12 August 2020 to 9,203 during 17-23 December 2020. The daily positivity rate the share of individuals tested and confirmed positive in the total number of individuals tested dropped from 12.7% on 1 August 2020 to 6.5% on 29 December 2020. Although the NPIs are driving down the number of cases, the risk of rapid spikes in new cases, similar to those in July 2020, remains. The new coronavirus variants, which have been observed to be more contagious, add to this risk. The introduction of COVID-19 vaccination is highly critical to lowering the number of new cases and bringing an end to the pandemic.

Impact

Health system performance in addressing public health outbreaks improved;

Protection of the public and reduction of COVID-19-related morbidity and mortality fostered; and

Economic growth and citizens' confidence restored

Project Outcome
Description of Outcome

Priority populations vaccinated against COVID-19.

Progress Toward Outcome
Implementation Progress
Description of Project Outputs

COVID-19 vaccines efficiently and effectively delivered.

Status of Implementation Progress (Outputs, Activities, and Issues)
Geographical Location Nation-wide
Safeguard Categories
Environment C
Involuntary Resettlement C
Indigenous Peoples C
Summary of Environmental and Social Aspects
Environmental Aspects
Involuntary Resettlement
Indigenous Peoples
Stakeholder Communication, Participation, and Consultation
During Project Design
During Project Implementation
Responsible ADB Officer Banzon, Eduardo P.
Responsible ADB Department Sectors Group
Responsible ADB Division Human and Social Development Sector Office (SG-HSD)
Executing Agencies
Department of Health
Timetable
Concept Clearance -
Fact Finding 14 Jan 2021 to 14 Jan 2021
MRM 08 Feb 2021
Approval 25 Mar 2021
Last Review Mission -
Last PDS Update 11 Mar 2021

Loan 4050-PHI

Milestones
Approval Signing Date Effectivity Date Closing
Original Revised Actual
11 Mar 2021 19 Mar 2021 15 Apr 2021 30 Sep 2024 - 13 Dec 2023
Financing Plan Loan Utilization
Total (Amount in US$ million) Date ADB Others Net Percentage
Project Cost 464.17 Cumulative Contract Awards
ADB 400.00 29 Apr 2024 393.45 0.00 100%
Counterpart 64.17 Cumulative Disbursements
Cofinancing 0.00 29 Apr 2024 393.45 0.00 100%
Status of Covenants
Category Sector Safeguards Social Financial Economic Others
Rating - Satisfactory Satisfactory - - Satisfactory

Loan 4163-PHI

Milestones
Approval Signing Date Effectivity Date Closing
Original Revised Actual
13 Dec 2021 14 Dec 2021 25 Jan 2022 30 Sep 2024 - -
Financing Plan Loan Utilization
Total (Amount in US$ million) Date ADB Others Net Percentage
Project Cost 299.37 Cumulative Contract Awards
ADB 250.00 29 Apr 2024 0.00 0.00 0%
Counterpart 49.37 Cumulative Disbursements
Cofinancing 0.00 29 Apr 2024 0.00 0.00 0%

Loan 8394-PHI

Milestones
Approval Signing Date Effectivity Date Closing
Original Revised Actual
25 Mar 2021 26 Mar 2021 10 May 2021 30 Sep 2024 - 26 Jan 2024
Financing Plan Loan Utilization
Total (Amount in US$ million) Date ADB Others Net Percentage
Project Cost 300.00 Cumulative Contract Awards
ADB 0.00 29 Apr 2024 0.00 295.63 100%
Counterpart 0.00 Cumulative Disbursements
Cofinancing 300.00 29 Apr 2024 0.00 295.63 100%
 
This page was generated from /projects/54171-003/main on 05 May 2024

Source URL: https://www.adb.org/projects/54171-003/main